Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Continuous Growth through Innovation
Continuous Growth through Innovation Thomas Schinecker | CEO Roche Group Octavian Seminar, 11 January 2024
Slide 4: Delivering on Innovation Promise; Opportunities for Future Growth; Outlook
Delivering on Innovation Promise Opportunities for Future Growth Outlook
Slide 5: Roche delivered consistent growth through biosimilar erosion
Roche delivered consistent growth through biosimilar erosion Successful diversification of our portfolio From three oncology assets driving ~50% of … to a diversified portfolio with assets that sales in 2012… span multiple therapeutic areas today From seven blockbusters…… … sixteen blockbusters Diag
Slide 6: Reallocating significant resources to R&D
Reallocating significant resources to R&D While defending margins and managing an exceptional patent cliff Roche Group growth FY 2022 vs. FY 2018 Note: Effective 1 January 2023, the Group made presentational and cost allocation changes to the income statement. The comparative information for 2022 wa
Slide 7: Young marketed and diversified portfolio driving Pharma growth
Young marketed and diversified portfolio driving Pharma growth Keeping historic launch momentum with two NMEs approved in 2023 CHFm % of Pharma Sales** 18,000 50% 16,000 42% 14,000 12,000 34% 10,000 23% 8,000 * 6,000 4,000 2,000 0 YTD Sep 2020 YTD Sep 2021 YTD Sep 2022 YTD Sep 2023 Potential NME app
Slide 8: Pharma pipeline assets by innovation potential
Pharma pipeline assets by innovation potential Roche ranks #2 having 36 NMEs with first-in-class potential Total number of pipeline assets by innovation potential*, # First-in-class Fast-follower Others* Peer 1 45 11 15 36 17 45 98 Peer 2 34 7 20 Peer 3 33 23 21 Peer 4 29 7 60 Peer 5 25 10 14 Peer 6
Slide 9: R&D Excellence to accelerate delivery of our medicines
R&D Excellence to accelerate delivery of our medicines 1 2 3 Set ambitious Strengthen portfolio Transform portfolio R&D objectives framework management & governance 4 5 6 Access the best Optimize R&D engines and Evolve talent, culture and external innovation invest in emerging technologies mindset t
Slide 10: Levers to drive R&D excellence are being implemented
Levers to drive R&D excellence are being implemented E.g., go/no go decisions based on E.g., leverage RWD and AI to increase E.g., focus on assets with best-in- critical review of scientific and research output and focus on clinical stage disease and first-in-class potential, commercial risk externa
Slide 11: Pipeline acceleration via partnering
Pipeline acceleration via partnering Deals of the past two years increasingly focused on clinical stage NMEs* H2 2023 Development stage Current Immunology Cardiovascular & Metabolism Oncology / Hematology Ophthalmology Positive proof of concept data at time of deal development stage *Table shows cli
Slide 12: Delivering on Innovation Promise; Opportunities for Future Growth; Outlook
Delivering on Innovation Promise Opportunities for Future Growth Outlook
Slide 13: Roche portfolio: Significant growth opportunities ahead
Roche portfolio: Significant growth opportunities ahead Key pipeline projects with upcoming near-term news flow • Mass spectrometry • Malignant Hematology: • Continuous Glucose Monitoring o Lunsumio, Columvi, Polivy in NHL • Next Generatrion Sequencing • Solid tumors: • Core Lab & Molecular Lab o In
Slide 14: Roche portfolio: Diverse growth opportunities ahead
Roche portfolio: Diverse growth opportunities ahead Key pipeline projects with upcoming near-term news flow • Mass spectrometry • Malignant Hematology: • Continuous Glucose Monitoring o Lunsumio, Columvi, Polivy in NHL • Next Generatrion Sequencing • Solid tumors: • Core Lab & Molecular Lab o Inavol
Slide 15: Malignant hematology: Growing diversified portfolio
Hematology Malignant hematology: Growing diversified portfolio Hematologic tumor cases by subtype1 Ph III clinical development overview On-market portfolio 3% Pipeline molecules Ph I Ph II Ph III 12% 9% cevostamab Columvi + chemo (STARGLO) in 2L+ DLBCL 2024 7% forimtamig 14% Lunsumio + Polivy (SUNMO
Slide 16: Crovalimab: Global filing in PNH, first approval expected H1 2024
Hematology Crovalimab: Global filing in PNH, first approval expected H1 2024 PRO and pooled safety data reinforce positive Ph III (COMMODORE) results Broad development program Treatment benefit in PNH supported by PRO and safety data FACIT-Fatigue scores from baseline to Week 25 ASH 2023 PNH C5i-naï
Slide 17: Breast cancer: Opportunities to expand beyond HER2+
Oncology solid tumors Breast cancer: Opportunities to expand beyond HER2+ Breast cancer cases by subtype1 Ph III clinical development overview Novel mechanisms and technologies Ph I Ph II Ph III On-market portfolio Pipeline molecules Giredestrant + palbociclib (perservERA) in 1L ER+/HER2- mBC girede
Slide 18: Inavolisib in PI3K-mutant HR+ breast cancer
Oncology solid tumors Inavolisib in PI3K-mutant HR+ breast cancer Positive Ph III results in 1L with a PFS HR of 0.43 to be filed in US/EU Potential best-in-class PI3Kα inhibitor Ph III (INAVO120) results: Potency/selectivity (inavolisib vs. alpelisib) Progeression free survival (PFS) 58 Pi3Kα poten
Slide 19: Solid tumors: Tiragolumab program continues to expand
Oncology solid tumors Solid tumors: Tiragolumab program continues to expand Continued confidence in aTIGIT biological activity based on evidence to date First-in-class anti-TIGIT mAb Clinical development program • Tiragolumab blocks the binding of TIGIT to its ligand PVR • Tiragolumab activates T-ce
Slide 20: Roche portfolio: Diverse growth opportunities ahead
Roche portfolio: Diverse growth opportunities ahead Key pipeline projects with upcoming near-term news flow • Mass spectrometry • Malignant Hematology: • Continuous Glucose Monitoring o Lunsumio, Columvi, Polivy in NHL • Next Generatrion Sequencing • Solid tumors: • Core Lab & Molecular Lab o Inavol
Slide 21: Trontinemab in Alzheimer's disease
Neuroscience Trontinemab in Alzheimer’s disease First dose finding data for BrainshuttleTM anti-Aβ presented at CTAD Trontinemab Trontinemab is differentiated from conventional anti-Aβ mAbs (BrainshuttleTM anti-Aβ Ab) and other brain delivery technologies Blood BBB Brain tissue Homogeneous brain Inv
Slide 22: Trontinemab clears amyloid more rapidly than conventional mAbs
Neuroscience Trontinemab clears amyloid more rapidly than conventional mAbs BrainshuttleTM AD study results in comparison to other anti-Aβ mAb PhIII trial results Amyloid PET positivity treshold (24 CL) Gantenerumab GRADUATE I /II: presentation at CTAD 2022, publication in preparation; Lecanemab CLA
Slide 23: Roche portfolio: Diverse growth opportunities ahead
Roche portfolio: Diverse growth opportunities ahead Key pipeline projects with upcoming near-term news flow • Mass spectrometry • Malignant Hematology: • Continuous Glucose Monitoring o Lunsumio, Columvi, Polivy in NHL • Next Generatrion Sequencing • Solid tumors: • Core Lab & Molecular Lab o Inavol
Slide 24: Ophthalmology: Pipeline gaining momentum with new data in 2024
Ophthalmology Ophthalmology: Pipeline gaining momentum with new data in 2024 Susvimo to be relaunched in AMD and filed in DME and DR in 2024 in the US Phase I Phase II Phase III Launched NME anti-IL-6 Vabysmo Vabysmo RG6351 RG6179 RG7716 RG7716 Retinal disease DME BRVO nAMD NME OpRegen1 Vabysmo Vaby
Slide 25: Roche portfolio: Diverse growth opportunities ahead
Roche portfolio: Diverse growth opportunities ahead Key pipeline projects with upcoming near-term news flow • Mass spectrometry • Malignant Hematology: • Continuous Glucose Monitoring o Lunsumio, Columvi, Polivy in NHL • Next Generatrion Sequencing • Solid tumors: • Core Lab & Molecular Lab o Inavol
Slide 26: Immunology: Gazyva Ph III results in lupus nephritis in 2024
Immunology Immunology: Gazyva Ph III results in lupus nephritis in 2024 Potential benefit in autoimmune diseases through sustained B cell depletion Gazyva Ph II (NOBILITY) results in LN1 Clinical trial program (glycoengineered anti-CD20 mAb) Complete renal response Type II anti-CD20 region Indicatio
Slide 27: Roche portfolio: Diverse growth opportunities ahead
Roche portfolio: Diverse growth opportunities ahead Key pipeline projects with upcoming near-term news flow • Mass spectrometry • Malignant Hematology: • Continuous Glucose Monitoring o Lunsumio, Columvi, Polivy in NHL • Next Generatrion Sequencing • Solid tumors: • Core Lab & Molecular Lab o Inavol
Slide 28: Important launches in Diagnostics from 2024 onwards
Important launches in Diagnostics from 2024 onwards Diagnostics to deliver mid to high single digit growth in coming years Continuous glucose Next generation Core & Molecular Lab Mass spectrometry monitoring (CGM) sequencing (NGS) • Menu expansion driving growth, • First fully integrated and • Subcu
Slide 29: Delivering on Innovation Promise; Opportunities for Future Growth; Outlook
Delivering on Innovation Promise Opportunities for Future Growth Outlook
Slide 30: Pipeline outlook: Key late-stage assets with 1bn+ sales potential
Pipeline outlook: Key late-stage assets with 1bn+ sales potential* Oncology, Neuroscience, Immunology, Hematology Cardiometabolic Ophthalmology tiragolumab Elevidys astegolimab NSCLC, HCC, ESCC, SCCHN DMD COPD 9 late-stage NMEs with giredestrant fenebrutinib ASO Factor B CHF>2 bn each in peak HR+ BC
Slide 31: FY 2023 guidance confirmed
FY 2023 guidance confirmed Group sales growth1 Low single digit decline Core EPS growth1 Broadly in line with sales decline Dividend outlook Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER) 31
Slide 32: Doing now what patients need next
Doing now what patients need next